Key clinical point: Tafasitamab plus lenalidomide appears to be a well tolerated and effective immunomodulatory treatment option.

Major finding: Of those patients who received tafasitamab plus lenalidomide, 43% had a complete response and 18% had a partial response.

Study details: L-MIND is a multicenter, prospective, single-arm, phase 2 study.

Disclosures: The study was sponsored by MorphoSys AG. The authors reported fees and grants from a variety of pharmaceutical companies.

Commentary

“The L-MIND phase 2 study investigated the anti-CD19 monoclonal antibody tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who were ineligible for autologous stem cell transplant. This population has poor outcomes with standard therapies. Sixty percent of patients responded with a CR rate of 43%. The median duration of response was 21.7 months and 72% of patients responded for at least 12 months. Responses were observed in both germinal center and non-germinal center B-cell molecular subtypes of DLBCL as well as in both relapsed and refractory patients. The most common toxicity was neutropenia, typically managed with growth factor support. Tafasitimab and lenlidomide is a promising combination in relapsed or refractory DLBCL particularly given the durable responses reported.”

Sarah Rutherford, MD
Assistant Professor of Medicine, Weill Cornell Medicine

Dr. Rutherford has served as a consultant for Celgene.